Prognostic significance of electrophysiological study in drug-induced type-1 Brugada syndrome: a brief systematic review.
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
01 Nov 2024
01 Nov 2024
Historique:
received:
09
03
2024
accepted:
19
08
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
ppublish
Résumé
Risk stratification in drug-induced type-1 Brugada syndrome (BrS) patients is challenging. The role of electrophysiological study (EPS) is debated as the majority of drug-induced type-1 BrS patients would not be studied according to the latest recommendations. A complete systematic literature search was performed to gauge the EPS role in this population. Three subgroups were defined: positive-EPS group, negative-EPS group, no-EPS group. Among 1318 drug-induced type-1 BrS patients, no significant difference in the incidence rate of arrhythmic events was observed between groups (I2 = 45%, P for subgroup difference = 0.10) during a mean follow-up of 5.1 years, also considering symptomatic status. In long-term follow-up of drug-induced type-1 BrS patients, EPS does not seem to aid prognostic stratification.
Sections du résumé
BACKGROUND
BACKGROUND
Risk stratification in drug-induced type-1 Brugada syndrome (BrS) patients is challenging. The role of electrophysiological study (EPS) is debated as the majority of drug-induced type-1 BrS patients would not be studied according to the latest recommendations.
METHODS
METHODS
A complete systematic literature search was performed to gauge the EPS role in this population. Three subgroups were defined: positive-EPS group, negative-EPS group, no-EPS group.
RESULTS
RESULTS
Among 1318 drug-induced type-1 BrS patients, no significant difference in the incidence rate of arrhythmic events was observed between groups (I2 = 45%, P for subgroup difference = 0.10) during a mean follow-up of 5.1 years, also considering symptomatic status.
CONCLUSION
CONCLUSIONS
In long-term follow-up of drug-induced type-1 BrS patients, EPS does not seem to aid prognostic stratification.
Identifiants
pubmed: 39347725
doi: 10.2459/JCM.0000000000001665
pii: 01244665-202411000-00004
doi:
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
775-780Informations de copyright
Copyright © 2024 Italian Federation of Cardiology - I.F.C. All rights reserved.
Références
Brugada J, Campuzano O, Arbelo E, Sarquella-Brugada G, Brugada R. Present status of Brugada syndrome: JACC state-of-the-art review. J Am Coll Cardiol 2018; 72:1046–1059.
Mascia G, Bona RD, Ameri P, et al. Brugada syndrome and syncope: a practical approach for diagnosis and treatment. Europace 2021; 23:996–1002.
Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada Syndrome Registry. Circulation 2010; 121:635–643.
Russo V, Pafundi PC, Caturano A, et al. Electrophysiological study prognostic value and long-term outcome in drug-induced type 1 Brugada Syndrome: the IBRYD Study. JACC Clin Electrophysiol 2021; 7:1264–1273.
Takagi M, Sekiguchi Y, Yokoyama Y, Aihara N, Hiraoka M, Aonuma K. Japan Idiopathic Ventricular Fibrillation Study (J-IVFS) Investigators. The prognostic impact of single extra-stimulus on programmed ventricular stimulation in Brugada patients without previous cardiac arrest: multicentre study in Japan. Europace 2018; 20:1194–1200.
Sieira J, Ciconte G, Conte G, et al. Long-term prognosis of drug-induced Brugada syndrome. Heart Rhythm 2017; 14:1427–1433.
Kamakura S, Ohe T, Nakazawa K, et al. Brugada Syndrome Investigators in Japan. Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1-V3. Circ Arrhythm Electrophysiol 2009; 2:495–503.
Furushima H, Chinushi M, Hirono T, et al. Relationship between dominant prolongation of the filtered QRS duration in the right precordial leads and clinical characteristics in Brugada syndrome. J Cardiovasc Electrophysiol 2005; 16:1311–1317.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 2021; 10:89.
Cutler MJ, Eckhardt LL, Kaufman ES, et al. Clinical management of Brugada syndrome: commentary from the experts. Circ Arrhythm Electrophysiol 2023; 17:e012072.
Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (Programmed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol 2012; 59:37–45.
Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003; 108:3092–3096.
Viskin S, Adler A, Rosso R. Brugada burden in Brugada syndrome: the way to go in risk stratification? Heart Rhythm 2013; 10:1019–1020.
Delise P, Allocca G, Sitta N. Risk of sudden death in patients with Brugada type 1 electrocardiographic pattern and no previous cardiac arrest: is it high enough to justify an extensive use of prophylactic ICD? J Cardiovasc Med (Hagerstown) 2016; 17:408–410.
Tonelli L, Balla C, Farnè M, et al. SCN5A mutation is associated with a higher Shanghai Score in patients with type 1 Brugada ECG pattern. J Cardiovasc Med (Hagerstown) 2023; 24:864–870.
Russo V, Caturano A, Migliore F, et al. IBRYD Study Group. Long-term clinical outcomes of patients with drug-induced type 1 Brugada electrocardiographic pattern: a nationwide cohort registry study. Heart Rhythm 2024; 21:555–561.
Sieira J, Conte G, Ciconte G, et al. A score model to predict risk of events in patients with Brugada Syndrome. Eur Heart J 2017; 38:1756–1763.
Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. ESC Scientific Document Group. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Eur Heart J 2015; 36:2793–2867.
Ciconte G, Monasky MM, Santinelli V, et al. Brugada syndrome genetics is associated with phenotype severity. Eur Heart J 2021; 42:1082–1090.
Tadros R, Nannenberg EA, Lieve KV, et al. Yield and pitfalls of ajmaline testing in the evaluation of unexplained cardiac arrest and sudden unexplained death: single-center experience with 482 families. JACC Clin Electrophysiol 2017; 3:1400–1408.
Sroubek J, Probst V, Mazzanti A, et al. Programmed ventricular stimulation for risk stratification in the Brugada syndrome: a pooled analysis. Circulation 2016; 133:622–630.